Evidence map›Paper›PMID 37414361›Full record

ReviewAdvanced drug delivery reviews2023

mRNA: A promising platform for cancer immunotherapy.

Byoungjae Kong, Yelee Kim, Eun Hye Kim, Jung Soo Suk, Yoosoo Yang

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. In the age of mRNA vaccines: Linear or circular mRNA?Molecular therapy. Nucleic acids · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. RNA therapeutic targeting of recalcitrant and rare cancers.Exploration of targeted anti-tumor therapy · 2026
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Byoungjae KongCenter for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Yelee KimBiomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea; Department of Life Sciences, Korea University, Seoul 02841, Republic of Korea.
Eun Hye KimBiomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea; Department of Life Sciences, Korea University, Seoul 02841, Republic of Korea.
Jung Soo SukCenter for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA. Electronic address: jsuk@jhmi.edu.
Yoosoo YangBiomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea. Electronic address: ysyang@kist.re.kr.
Johns Hopkins University · USKorea University · KRKorea Institute of Science and Technology · KR

Funding

Nanocage-based systemic delivery of TGFβ trap for immunomodulation of brain neoplasmsR01NS119609 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI LIM, MICHAEL, SUK, JUNG SOO · 2021 to 2025
$2.4M
Localized SDF-1 mRNA nanoparticle delivery for treating erectile dysfunction.R01DK132425 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI HANNAN, JOHANNA LUCY, SUK, JUNG SOO · 2022 to 2025
$2.0M
NIDDK NIH HHS R01 DK132425NINDS NIH HHS R01 NS119609
6 · The paper itself

Abstract

Messenger RNA (mRNA) is now in the limelight as a powerful tool for treating various human diseases, especially malignant tumors, thanks to the remarkable clinical outcomes of mRNA vaccines using lipid nanoparticle technology during the COVID-19 pandemic. Recent promising preclinical and clinical results that epitomize the advancement in mRNA and nanoformulation-based delivery technologies have highlighted the tremendous potential of mRNA in cancer immunotherapy. mRNAs can be harnessed for cancer immunotherapy in forms of various therapeutic modalities, including cancer vaccines, adoptive T-cell therapies, therapeutic antibodies, and immunomodulatory proteins. This review provides a comprehensive overview of the current state and prospects of mRNA-based therapeutics, including numerous delivery and therapeutic strategies.

Indexed as

COVID-19NeoplasmsHumansImmunotherapyPandemicsRNA, MessengerRNA, Messenger

Identifiers

PMID37414361
PMCPMC11797636
OpenAlexW4383311353

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.